Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glimepiride + metformin + voglibose + ritonavir
- Development stage
- Unknown
- Lead developer
- Inventia Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This appears to be a combination of GVM 1 Tablet SR (containing glimepiride, metformin, and voglibose) with ritonavir. GVM 1 Tablet SR is an anti-diabetic medication used to treat type 2 diabetes mellitus. Ritonavir is a protease inhibitor initially developed for HIV treatment that is now primarily used as a pharmacokinetic booster for other antiretroviral medications.
- Other names
- GVM + R
02
Targets
Sucrase-IsomaltaseAMPK (Adenosine monophosphate–activated protein kinase)SUR1 (Sulfonylurea receptor 1)CYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)
Beyond the preview
Go deeper on glimepiride + metformin + voglibose + ritonavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glimepiride + metformin + voglibose + ritonavir.